Eli Lilly Acquires Psychedelic Company for $2.8 Billion

Eli Lilly Spends $2.8 Billion to Enter the Psychedelic Market

Eli Lilly has just made the largest corporate bet in history on the psychedelic drug market. The American pharmaceutical company announced the acquisition of AtaiBeckley for $2.8 billion in cash, paying $6.75 per share, a 26% premium over the last closing price. The deal also includes an additional payment of up to $1 billion if the developing drugs meet regulatory milestones.

The market reaction was immediate. AtaiBeckley shares opened up 33% in New York, while Eli Lilly's stock rose 2.4%. For a company that has multiplied its revenues in recent years with weight loss pens, this operation represents a strategic return to neurology, a field it has been involved in since the launch of Prozac over three decades ago.

More than just an isolated bet, this move signals that the traditional pharmaceutical industry is willing to pay a high price to not miss out on a segment that, according to Bloomberg Intelligence analysts, could reach $7 billion in sales by 2032. The acquisition is part of a broader program: Eli Lilly has informed shareholders that it intends to spend up to $25 billion on mergers and acquisitions this year.

What Makes AtaiBeckley So Valuable

AtaiBeckley was born from the merger of Atai Life Sciences and Beckley Psytech, led by German entrepreneur Christian Angermayer. Among the investors is Peter Thiel, co-founder of PayPal and one of the most influential figures in Silicon Valley. The company is valued at $2.6 billion on the stock market and has three drugs in development aimed at mental health disorders.

The main one is BPL-003, a nasal spray based on 5-MeO-DMT, a psychedelic found in certain plants and in the venom of the Bufo alvarius toad, known as the Sonoran Desert toad. The product is in the third phase of clinical trials, with initial results expected by 2029. In earlier stages, patients reported significant improvement in symptoms of treatment-resistant depression within two days after a single dose.

Two aspects stand out to analysts. First, the positive effects persisted for up to eight weeks, according to participant reports. Second, the psychedelic experience lasted between one and two hours, much less than the eight hours of observation required for similar drugs. This reduced time could be a relevant competitive advantage. Spravato, Johnson & Johnson's nasal spray based on esketamine that is already on the market for treatment-resistant depression, requires at least two hours of monitoring.

Ayahuasca, MDMA, and the Complete Pipeline

In addition to BPL-003, AtaiBeckley is developing two other experimental drugs. VLS-01 is a dissolvable film based on DMT, the active ingredient in ayahuasca, intended for the treatment of treatment-resistant depression through another route. EMP-01 is a capsule based on MDMA, the substance found in ecstasy, aimed at treating social phobia.

This diversified pipeline explains part of the value attributed to the company. As detailed in our coverage of the financial sector, acquisitions of companies with multiple drug candidates tend to carry higher premiums, even when none of the products have reached the market.

AtaiBeckley is not alone in this segment. Companies like Definium Therapeutics and AbbVie are also exploring the development of psychedelic drugs. The sector gained additional momentum after President Trump signed an executive order to accelerate research in the area, a move that has reshaped the regulatory dynamics for alternative mental health treatments.

What This Acquisition Says About the Pharmaceutical Market

The operation reveals two intersecting trends. The first is the pharmaceutical industry's search for new growth frontiers. Eli Lilly has found in weight loss pens (Mounjaro and Zepbound) an extraordinary revenue machine, but it knows that diversification is essential to sustain its long-term valuation. Returning to neurology, where it built its reputation with Prozac, makes strategic sense.

The second trend is the legitimization of psychedelics as a therapeutic class. For decades, substances like DMT, MDMA, and psilocybin were restricted to marginal research. The landscape has changed. Clinical trials with promising results and regulatory support from the U.S. government have created a window for large companies to enter this market without the reputational risk that existed before.

For investors, the signal is clear: the mental health segment based on psychedelics is moving out of the speculative phase. When a company the size of Eli Lilly, with a market capitalization exceeding $700 billion, pays nearly $4 billion (considering earnouts) for a company without approved products, the message is that regulatory odds are seen as favorable.

What is the impact for those following the sector

The therapeutic psychedelics market is still small, but Eli Lilly's entry acts as a validation seal. It is the type of operation that typically triggers a wave of M&As in the same segment, as we have documented in other acquisition races in the healthcare sector.

The next milestones to watch are the phase 3 results of BPL-003, expected in 2029, and regulatory advancements in the United States. If the FDA approves the first psychedelic drug from a big pharma, the impact on the sector will be similar to what the approval of GLP-1 represented for the obesity market.

The difference is that this time, the product in question is derived from the venom of a desert toad from Arizona. The pharmaceutical market is definitely not what it used to be.